Literature DB >> 27887976

The establishment of a telestroke service using multimodal CT imaging decision assistance: "Turning on the fog lights".

Jelle Demeestere1, Claire Sewell2, Jennifer Rudd3, Timothy Ang1, Louise Jordan4, James Wills3, Carlos Garcia-Esperon1, Ferdinand Miteff1, Venkatesh Krishnamurthy1, Neil Spratt5, Longting Lin6, Andrew Bivard6, Mark Parsons5, Christopher Levi7.   

Abstract

Telestroke services have been shown to increase stroke therapy access in rural areas. The implementation of advanced CT imaging for patient assessment may improve patient selection and detection of stroke mimics in conjunction with telestroke. We implemented a telestroke service supported by multimodal CT imaging in a rural hospital in Australia. Over 21months we conducted an evaluation of service activation, thrombolysis rates and use of multimodal imaging to assess the feasibility of the service. Rates of symptomatic intracranial haemorrhage and 90-day modified Rankin Score were used as safety outcomes. Fifty-eight patients were assessed using telestroke, of which 41 were regarded to be acute ischemic strokes and 17 to be stroke mimics on clinical grounds. Of the 41 acute stroke patients, 22 patients were deemed eligible for thrombolysis. Using multimodal CT imaging, 8 more patients were excluded from treatment because of lack of treatment target. Multimodal imaging failed to be obtained in one patient. For the 14 treated patients, median door-imaging time was 38min. Median door-treatment time was 91min. A 90-day mRS ⩽2 was achieved in 40% of treated patients. We conclude that a telestroke service using advanced CT imaging for therapy decision assistance can be successfully implemented in regional Australia and can be used to guide acute stroke treatment decision-making and improve access to thrombolytic therapy. Efficiency and safety is comparable to established telestroke services.
Copyright © 2016. Published by Elsevier Ltd.

Entities:  

Keywords:  CT perfusion; Reperfusion therapy; Telemedicine; Telestroke; Thrombectomy; Thrombolysis

Mesh:

Substances:

Year:  2016        PMID: 27887976     DOI: 10.1016/j.jocn.2016.10.018

Source DB:  PubMed          Journal:  J Clin Neurosci        ISSN: 0967-5868            Impact factor:   1.961


  4 in total

Review 1.  Telestroke.

Authors:  Oana M Dumitrascu; Bart M Demaerschalk
Journal:  Curr Cardiol Rep       Date:  2017-09       Impact factor: 2.931

2.  Test characteristics of a 5-element cortical screen for identifying anterior circulation large vessel occlusion ischemic strokes.

Authors:  Jessica Hoglund; Dale Strong; Jeremy Rhoten; Brenda Chang; Rahul Karamchandani; Connell Dunn; Hongmei Yang; Andrew W Asimos
Journal:  J Am Coll Emerg Physicians Open       Date:  2020-07-24

3.  Implementation of multimodal computed tomography in a telestroke network: Five-year experience.

Authors:  Carlos Garcia-Esperon; Frode Soderhjelm Dinkelspiel; Ferdi Miteff; Shyam Gangadharan; Tom Wellings; Bill O Brien; James Evans; Tom Lillicrap; Jelle Demeestere; Andrew Bivard; Mark Parsons; Chris Levi; Neil James Spratt
Journal:  CNS Neurosci Ther       Date:  2019-09-30       Impact factor: 5.243

4.  TACTICS - Trial of Advanced CT Imaging and Combined Education Support for Drip and Ship: evaluating the effectiveness of an 'implementation intervention' in providing better patient access to reperfusion therapies: protocol for a non-randomised controlled stepped wedge cluster trial in acute stroke.

Authors:  Annika Ryan; Christine L Paul; Martine Cox; Olivia Whalen; Andrew Bivard; John Attia; Christopher Bladin; Stephen M Davis; Bruce C V Campbell; Mark Parsons; Rohan S Grimley; Craig Anderson; Geoffrey A Donnan; Christopher Oldmeadow; Sarah Kuhle; Frederick R Walker; Rebecca J Hood; Steven Maltby; Angela Keynes; Candice Delcourt; Luke Hatchwell; Alejandra Malavera; Qing Yang; Andrew Wong; Claire Muller; Arman Sabet; Carlos Garcia-Esperon; Helen Brown; Neil Spratt; Timothy Kleinig; Ken Butcher; Christopher R Levi
Journal:  BMJ Open       Date:  2022-02-11       Impact factor: 2.692

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.